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Abstract
Background: Hydrodynamic injection is an effective method for DNA delivery in mouse liver and is being translated to
larger animals for possible clinical use. Similarly, QC31 integrase has proven effective in mediating long-term gene therapy
in mice when delivered by hydrodynamic injection and is being considered for clinical gene therapy applications. However,
chromosomal aberrations have been associated with QC31 integrase expression in tissue culture, leading to questions about
safety.
Methodology/Principal Findings: To study whether hydrodynamic delivery alone, or in conjunction with delivery of QC31
integrase for long-term transgene expression, could facilitate tumor formation, we used a transgenic mouse model in which
sustained induction of the human C-MYC oncogene in the liver was followed by hydrodynamic injection. Without injection,
mice had a median tumor latency of 154 days. With hydrodynamic injection of saline alone, the median tumor latency was
significantly reduced, to 105 days. The median tumor latency was similar, 106 days, when a luciferase donor plasmid and
backbone plasmid without integrase were administered. In contrast, when active or inactive QC31 integrase and donor
plasmid were supplied to the mouse liver, the median tumor latency was 153 days, similar to mice receiving no injection.
Conclusions/Significance: Our data suggest that QC31 integrase does not facilitate tumor formation in this C-MYC
transgenic mouse model. However, in groups lacking QC31 integrase, hydrodynamic injection appeared to contribute to C-
MYC-induced hepatocellular carcinoma in adult mice. Although it remains to be seen to what extent these findings may be
extrapolated to catheter-mediated hydrodynamic delivery in larger species, they suggest that caution should be used
during translation of hydrodynamic injection to clinical applications.
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Introduction
Hydrodynamic injection of plasmid DNA involves a rapid,
high-volume injection of DNA into the tail vein of mice [1,2]. This
method can provide delivery of DNA to as many as 40% of
hepatocytes and has been widely adopted for delivery of nucleic
acids to mouse liver. In addition, catheter-mediated adaptations of
the method have been developed for DNA delivery in larger
animals, opening the possibility of clinical use for gene therapy [3].
Several groups have reported successful gene delivery to the pig
liver [4–7], and a Phase I clinical trial has been conducted in
thrombocytopenia patients [6].
Use of QC31 integrase in conjunction with hydrodynamic
delivery offers a strategy to make gene delivery in hepatocytes
permanent, by bringing about covalent integration of the plasmid
DNA into the chromosomes [8,9]. QC31 integrase is a large serine
recombinase that is capable of integrating attB-containing donor
plasmids into pseudo attP sites that occur endogenously in
mammalian chromosomes [10]. Because its mechanism of
integration requires DNA sequence recognition, QC31 integrase
has a more restricted integration profile than other integrating
vectors such as retroviruses and transposons [11]. The more
limited number of potential integration sites may make QC31
integrase less likely to activate an oncogene or disrupt a tumor
suppressor gene.
Both hydrodynamic injection and QC31 integrase are relatively
new technologies that have not yet been rigorously tested for their
potential tumorigenicity. To date, hydrodynamic delivery has not
been associated with increased cancer risk. Similarly, QC31
integrase has been used in many pre-clinical gene therapy studies
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cancer incidence [10]. In a recent study, QC31-modified human
cord-lining epithelial cells failed to form tumors in SCID mice
[12]. The same study also analyzed microarray data and found
that three tumor suppressor gene transcripts were upregulated in
QC31-modified cells [12]. Nevertheless, after prolonged expression
of QC31 integrase in cultured cells, chromosomal rearrangements
were found by both plasmid rescue and karyotyping [11,13–15]. If
such aberrations occurred in vivo, they could increase cancer risk
by contributing to genomic instability. Therefore, it was of interest
to analyze with greater sensitivity whether exposure to hydrody-
namic injection or QC31 integrase could stimulate tumorigenesis
in an appropriate animal model.
In studies not designed to evaluate cancer risk, cancers have
appeared after injection of viral gene therapy vectors in utero or in
neonatal mice [16,17]. By contrast, in this study we specifically
tested whether hydrodynamic injection and/or QC31 integrase
were capable of contributing to MYC-induced tumorigenesis in
adult mice in a previously validated animal model. This approach
is similar to studies that have investigated the potential
contribution of various gene therapy vectors to blood cancer
formation, which occurred during a clinical trial that employed
retroviral vectors to treat children with X-linked severe combined
immunodeficiency [18–20]. Small molecule carcinogens, shRNA,
and partial hepatectomy have all been demonstrated in separate
studies to contribute to MYC-induced hepatocellular carcinoma
using the same model and similar methods to those used in this
study [21–23].
Mice transgenic for both TRE-MYC [24] and LAP-tTA [25]
have been developed as a mouse model for hepatocellular
carcinoma in which the human C-MYC transcription factor is
expressed in the liver when doxycycline is absent [26]. In this
mouse model, the tumor latency is long enough that subtle
oncogenic perturbations would be detectable, yet short enough to
be experimentally tractable [23]. C-MYC is genomically amplified
in up to 50% of human liver tumors, and this amplification can
result in C-MYC overexpression [27,28]. The C-MYC transcrip-
tion factor plays a key role in development by inducing genes that
control cell division, growth, and apoptosis [29]. When disregu-
lated in blood cancers, C-MYC has been shown to contribute to
the formation of double-strand breaks [30]. Hepatocellular
carcinomas initiated in this model were found to regress when
C-MYC expression was terminated [26,31]. We asked whether
hydrodynamic delivery, either with or without QC31 integrase,
might cooperate with C-MYC to accelerate tumor formation in
this mouse model.
Materials and Methods
Ethics Statement
The Stanford Administrative Panel on Laboratory Animal Care
approved all procedures performed on animals in protocol
number 9477, assurance number A3213-01. The Stanford
Comparative Medicine program is accredited by the Association
for Accreditation and Assessment of Laboratory Animal Care
International.
Plasmids
pCS, pCSmI, and pCSI have been described previously [32,33].
Briefly, these plasmids carry ampicillin resistance and contain a
CMV promoter and SV40 poly-A tail (pCS), between which either
mutant S20F (pCSmI) or wild-type (pCSI) QC31 integrase was
cloned. pLiLucB is a liver-specific, luciferase-expressing attB donor
plasmid that was constructed by digesting pNBL2 [34] with XhoI
to remove the CMV promoter and digesting pVFB [35] with
EcoRI to obtain the human alpha-1 antitrypsin promoter with an
apolipoprotein enhancer. The ends of both fragments were made
blunt by filling in with Klenow polymerase, and the pNBL2
backbone was treated with phosphatase. The construct was ligated
using T4 ligase and checked by XcmI digestion and sequencing of
the promoter region.
Mouse experiments
Genotyped LAP-tTA homozygous females were bred to
genotyped TRE-MYC males (the TRE-MYC transgene is on the
Y chromosome) to give male mice having one copy of each gene.
All mice were on the FVB/N strain background. A solution of
doxycycline hyclate (Sigma-Aldrich, St. Louis, MO) was given as
drinking water at a concentration of 100 mg/ml from one week
before mating cages were set up until after weaning at 7–8 weeks
of age. Autoclaved paper tubes were placed in mouse cages to
prevent fighting. Mice were randomly assigned to groups in
random order. Each experimental group consisted of mice from
between 3–8 separate litters. Hydrodynamic injections were
carried out as previously described [36] using a heat lamp for
tail vein dilation, with the exception that sterile phosphate-
buffered saline #20012 (Invitrogen, Carlsbad, CA) was used to
dilute the DNA. Live animal imaging was done on the IVIS 200
machine (Caliper Life Sciences, Alameda, CA). Animals in groups
given luciferase were imaged on one of eight separate imaging
schedules, consisting of between 1–3 experimental groups per
imaging schedule. The mice were imaged at Day 1, Week 1, 2, 4,
6, 8, 10, 12, 14, 17, 20, etc. until sacrifice. Mice were monitored
weekly for abdominal swelling and/or other signs of distress and
sacrificed when it was believed that they would not survive another
week. After dissection, portions of the normal liver, liver tumors,
and metastatic tumors (if present) were fixed for histology as
previously described [36], and snap frozen in a dry ice/
isopropanol bath for subsequent genomic DNA and protein
analysis.
Luciferase assay
Protein was prepared from tissue samples using the lysis buffer
previously described [35] and homogenized with a Kontes pellet
pestle motor (VWR, Batavia, IL). Protein prepared from
transfected HeLa cells (ATCC, Manassas, VA), producing
luciferase from the pNBL2 plasmid after FuGene 6 (Roche,
Indianapolis, IN) transfection, was used as the positive control.
Protein concentrations were determined by the Bradford method
with Protein Assay Reagent (Biorad, Hercules, CA). 15 mgo f
protein were added per well. The luciferase assay kit procedure
was run in quadruplicate on a 96-well plate reader according to
the manufacturer’s instructions (Promega, Madison, WI).
PCR analysis
Total DNA was prepared from normal-appearing liver and
tumor samples using the DNeasy Blood and Tissue Kit according
to the manufacturer’s directions, including the optional addition of
RNase (Qiagen, Valencia, CA). DNA concentrations were
measured using the Nanodrop (Thermo Scientific, Wilmington,
DE). 200 ng of DNA was added to each PCR reaction, prepared
according to manufacturer’s directions using illustra puReTaq
Ready-To-Go PCR beads (GE Healthcare, Piscataway, NJ). To
detect the luciferase-bearing plasmid pLiLucB in the genomic
DNA, the forward primer 59GACCGTGACCTACATCGTC
and the reverse primer 59-CATGTCTGCTCGAAGCGGC were
used to amplify the luciferase gene. The template used for the
second round in the nested mpsL1 PCR was 1 ml of a 1:10 dilution
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mpsL1 and to detect GAPDH have been previously described
[37]. The reactions were carried out at least twice for all samples.
Results
In our previous studies, dozens of wild-type mice have received
hydrodynamic injections, with or without integrase [8,35,36,38]. Of
these mice, as well as many more mice treated similarly in lab
studies that have not beenpublished,no liver tumorshaveeverbeen
observed.Therefore,forgreatersensitivity,a mousemodel wasused
in which all mice would develop tumors. Different groups were
trackedtoprovidesurvivaltimesthatcouldbecomparedstatistically
to determine if the treatments had an effect on the length of time
between induction of C-MYC expression in the liver and sacrifice
due to tumor burden, a time frame defined in this study as ‘‘tumor
latency.’’ We hypothesized that since QC31 integrase is associated
with chromosomal aberrations in tissue culture, its expression might
decrease tumor latency in these tumor-prone mice.
LAP-tTA/TRE-MYC double transgenic, male mice were given
doxycycline drinking water from conception until 7–8 weeks of age
to suppress C-MYC expression in the liver during development,
which would have been lethal (Fig. 1a) [22]. Complete regulation
of C-MYC expression by doxycycline was previously observed to
have a time scale of four days [22,26]. Therefore, at one week after
initiation of sustained C-MYC induction, a hydrodynamic
injection [1,2] was administered containing no plasmid (saline
only) or 20 mg each of a luciferase-expressing donor plasmid
(pLiLucB) and plasmids containing vector backbone alone (pCS),
expressing inactive integrase (pCSmI), or active wild-type integrase
(pCSI) (Fig. 1b). One group was given the active integrase
plasmid pCSI alone (20 mg). The DNA dose of 20 mg per plasmid
has been used to confer therapeutic levels of hFIX using QC31
integrase in mice [9]. Two groups were not given hydrodynamic
injection: one was given doxycycline drinking water for 7–8 weeks,
and another was given doxycycline drinking water for one year.
Mice that were injected with pLiLucB were imaged the next day to
confirm high levels of luciferase expression in the liver, indicating a
successful hydrodynamic injection. C-MYC induction preceded
integrase expression because the integrase protein can only be
detected by Western blot for up to one day after hydrodynamic
injection [39].
Mice were monitored weekly for tumor formation. The animals
were sacrificed when it was expected that they would not have
survived another week, as indicated by swelling in the upper
abdomen (Fig. 1a) or signs of morbidity. Most of the mice with
extensive hepatocellular carcinoma appeared behaviorally normal
until the point of sacrifice. At autopsy, mice were dissected,
photographed, and examined for the presence of liver tumors.
Most tumors were multifocal, presumably arising from different
tumor-forming cells (Fig. 1a), as has been suggested previously
[22,23,26]. No differences in gross type, number, size, mass or
distribution of tumors were observed between groups. Imaging
was done every 2–3 weeks to monitor whether luciferase
expression was observed in locations outside of the liver, indicating
a possible luciferase-positive metastasis. Although several cases of
metastasis were observed upon dissection (Table 1), none were
detectable by luciferase imaging.
The seven groups of mice were observed for tumor formation to
distinguish the effects of C-MYC induction, hydrodynamic
injection, DNA administration, QC31 integrase protein, and
QC31 integrase activity (Fig. 2a). To make these effects easier
to evaluate, we have separated the composite Kaplan-Meier
survival curve (Fig. 2g) into several plots comparing these effects
in a step-wise manner.
Hydrodynamic delivery significantly decreased tumor
latency
The survival times of mice in the control groups are compared
in Figure 2b. The animals that did not receive C-MYC induction
or any injections (yellow) survived until the end of the study, 400
Figure 1. Experimental design of tumorigenesis assay. (a)
Transgenic mice were taken off of doxycycline drinking water at 7–8
weeks of age to induce expression of the human C-MYC transgene
specifically in the liver from the LAP promoter, except for one control
group (MYC off). Exactly one week after C-MYC induction, all groups
except one control group (MYC on, no injection) were given
hydrodynamic injections of phosphate-buffered saline alone or DNA
plasmids diluted in phosphate-buffered saline. Mice were monitored
weekly, imaged every two or three weeks, and sacrificed when tumors
were detectable by gross distention of the abdomen as pictured. Inset
shows the dissected liver and tumors from the pictured mouse, which
was representative of all mice in all groups. (b) The plasmids given by
hydrodynamic injection and their features.
doi:10.1371/journal.pone.0011367.g001
Table 1. Treatment group and number of days from initiation
of C-MYC overexpression until sacrifice (survival time) for each
case of metastasis.
Group Number of metastasis Survival time (days)
no injection 1 209
saline injection 0
pCS/pLiLucB 0
pCSmI/pLiLucB 3 111, 139, 329
pCSI/pLiLucB 1 258
pCSI alone 1 164
doi:10.1371/journal.pone.0011367.t001
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expression in the liver beginning at adulthood (7–8 weeks) resulted
in all of the mice being sacrificed prior to the end of the study with
a median tumor latency of 154 days. These results confirmed that
the LAP-tTA/TRE-MYC mouse model allowed for tight oncogene
regulation.
Interestingly, in the group of mice that received a hydrodynamic
injection of phosphate-buffered saline without any DNA present,
the median tumor latency was only 105 days. There was one
mouse that survived past 200 days that may have been an
exception in some way, for example, by receiving an unsuccessful
hydrodynamic injection. Similarly, a single long-surviving mouse
was seen in other groups. To keep these outliers from having
major effects on statistical significance, we chose the Gehan-
Breslow-Wilcoxon statistical test to compare survival times,
because this test gives less weight to later events. The group in
which C-MYC was turned ‘‘on’’ and no treatment was given
(orange) was statistically different than the group that had C-MYC
‘‘on’’ and received saline-only hydrodynamic injection (red;
p=0.0359), indicating that there was a significant decrease in
tumor latency associated with the hydrodynamic delivery method.
DNA delivery, luciferase expression, and imaging did not
affect tumor latency
To test the effect on tumor latency of DNA without the
integrase gene, we gave the transgenic mice hydrodynamic
injections containing 20 mg each of pCS and pLiLucB (Fig. 1b).
Inclusion of this group was intended to control for both the
integrase plasmid backbone elements as well as firefly luciferase
expression and imaging every 2–3 weeks, which entailed injections
of luciferin and anesthesia with isoflurane for a period of
approximately 15 minutes. As shown in Figure 2c, the saline-
only (red) and pCS/pLiLucB (purple) groups had nearly identical
survival curves, except for one late survivor in the saline-only
group. The pCS/pLiLucB group was statistically significantly
different than the MYC ‘‘on’’, no injection group (p=0.014),
again implicating effects of the hydrodynamic injection.
Integrase expression resulted in similar tumor latency to
that of untreated mice
To evaluate the effect of QC31 integrase protein expression
independent of integration activity, we injected the plasmids
pCSmI and pLiLucB (Fig. 1b) into a group of C-MYC expressing
mice (Fig. 2d, cyan). The pCSmI plasmid has a S20F mutation in
the catalytic serine, rendering the QC31 integrase made by this
plasmid unable to recombine DNA. We observed a statistically
significant increase in tumor latency when inactive integrase
protein was present, compared to the saline-only group
(p=0.045). Again, note that we observed a very late surviving
mouse in this group, which lived about twice as long as the second-
longest surviving mouse in the group.
When the pCSI constructencodingactive integrase (Fig. 1b)w a s
administered with the pLiLucB donor plasmid (blue, Fig. 2d), the
tumor latency also increased compared to the saline only group.
According to the Gehan-Breslow-Wilcoxon test of statistical
significance, the pCSmI/pLiLucB and pCSI/pLiLucB groups were
not significantly different. To test if recombination of plasmid DNA
was necessary for the observed survival benefit, we also adminis-
tered 20 mg of pCSI without any attB donor plasmid (green) to a
cohort of TRE-MYC/LAP-tTA mice. Presence of the attB-containing
plasmid appeared to have no effect on survival (Fig. 2e).
To summarize, the C-MYC ‘‘on’’, pCSI/pLiLucB group was not
statistically different than the C-MYC ‘‘on’’, no injection group
(Fig. 2f), indicating that the presence of integrase appeared to
counteract the tumor acceleration due to hydrodynamic injection.
Hydrodynamic injection without integrase expression yielded a
survival curve that was significantly different than the uninjected
and pCSI/pLiLucB groups. The acceleration of tumor formation
in mice that received a hydrodynamic injection appeared to be
somehow abrogated by expression of the integrase. All groups are
graphed together in Fig. 2g on a longer x-axis.
Tumors did not have luciferase activity or QC31
integrase-mediated integration events
In order to investigate further whether QC31 integrase played any
role in tumor formation, we analyzed tumors isolated from mice in
the pCSI/pLiLucB group. We tested protein extracts from eight
tumors and one metastasis from four mice in this group and found
that none of them were positive for luciferase activity (Fig. 3a).
Additionally, we were unable to detect the luciferase gene by PCR in
the six tumors from three mice in the pCSI/pLiLucB group that were
tested (Fig. 3b).ThisPCRwoulddetectintegrationatanylocationin
t h eg e n o m e .T h et u m o r st h a tt e s t e dn e g a t i v ef o rl u c i f e r a s ea c t i v i t y
included the six tumors that tested negative for the presence of the
luciferase gene, suggesting that the luciferase donor plasmid was not
integratedandsilencedinthesetumors.TodeterminefurtherifQC31
integrase mediated integration of plasmid DNA into the cells that
generated tumors, we tested all dissected tumors for integration into
the dominant pseudo attP site in the mouse liver genome known as
mpsL1 [9], using a nested PCR. For each round, one primer was in
the mouse genome at mpsL1 while the other primer was the in attB
sequence in the donor plasmid. PCR analysis was performed on
DNA isolated from 19 tumors from 9 mice, including 7 tumors and 1
metastasis that were also tested for luciferase activity and six tumors
also tested by PCR for the presence of the luciferase gene. No mpsL1
integration was detected in any tumors. Integration was detected only
inDNAisolatedfromthenormal-appearingpartoftheliver(Fig.3c).
A GAPDH control demonstrated that a sufficient amount (200 ng) of
genomic DNA was added to each PCR reaction. Thus, no evidence
for QC31 integrase activity was found in any of the tumors from mice
in the pCSI/pLiLucB group, suggesting that QC31 integrase may not
have played a role in tumor formation in the LAP-tTA/TRE-MYC
transgenic mouse model.
Luciferase imaging data and correlation to tumor latency
Mice were imaged on day 1 and every two weeks thereafter for
luciferase expression for the first 14 weeks, followed by every three
weeks thereafter. We have shown the luciferase imaging data to
Figure 2. Survival curves suggest that hydrodynamic injection may contribute to C-MYC-induced tumor formation in the mouse
liver. (a) Key showing the number of animals (n), median survival time in days (Median), and statistical results for each group. The significance as
determined by the Gehan-Breslow-Wilcoxon test comparing each group to the MYC on, no injection (no inj?) or MYC on, saline injection (saline?)
control groups is given. (b) A comparison of MYC off, no injection (yellow), MYC on, no injection (orange), and MYC on, saline injection (red) survival
curves. (c) A comparison of MYC on, saline injection and MYC on, pCS/pLiLucB (purple) injection survival curves. (d) A comparison of MYC on, pCS/
pLiLucB, MYC on, pCSmI/pLiLucB (cyan), and MYC on, pCSI/pLiLucB (blue) survival curves. (e) The survival curves of groups given pCSI with and
without (green) donor plasmid. (f) A comparison of pCSI/pLiLucB to the control groups of no injection and saline-only injection. (g) The survival
curves of all groups shown on the same plot. All plots and statistics were done using GraphPad Prism software.
doi:10.1371/journal.pone.0011367.g002
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be sacrificed, thus complicating the data with increasing statistical
error as the group sizes decreased. Averaged luciferase values were
normalized to the day 1 luciferase value to remove variability on
account of transfection efficiency. The standard error was
calculated using propagation of errors to take this normalization
into account. pCSI/pLiLucB gave significantly higher long-term
expression than pCSmI/pLiLucB (Student’s t-test, p=0.014),
demonstrating that QC31 integrase was active in the mouse liver.
The pCS/pLiLucB and pCSmI/pLiLucB groups would still retain
some luciferase expression due to random integration of the
pLiLucB plasmid. The pCS/pLiLucB group maintained luciferase
values that were significantly higher than pCSmI/pLiLucB
(Student’s t-test, p=3610
25). It is unclear why these groups have
Figure 3. Luciferase activity and PCR analysis of tumors from mice in the pCSI/pLiLucB group provide no evidence of QC31
integrase activity. (a) Protein extracts were prepared and the luciferase activity was measured in absolute counts per second (CPS). Controls
included HeLa cells given FuGene 6 alone [HeLa (-)] or the CMV-luciferase plasmid pNBL2 via FuGene 6 [HeLa (+)], the normal-appearing part of the
tumor-ridden liver taken from either a saline-injected mouse [Liver (-)] and pCSI/pLiLucB-injected mouse [Liver (+)]. Eight tumor samples (Tumor 1
through 8) and one metastasis (Met 1) that were obtained from four animals were also analyzed. The error bars give standard error of the mean for
four replicates of each sample. (b) PCR analysis to detect the pLiLucB plasmid by amplification of the luciferase transgene. Plasmid DNA (20 ng
pLiLucB) and no DNA controls show specific amplification of luciferase only in the reaction containing plasmid. One mouse each from the saline-only
and pCSmI/pLiLucB groups was analyzed for transgene presence in normal-appearing (N) and tumor (T) tissues (none found). Three mice in the pCSI/
pLiLucB group were analyzed for transgene presence in normal-appearing (N) and tumor (T) tissues. Luciferase could be detected in 2/3 normal-
appearing liver samples and none of the tumors. (c) PCR analysis for integration at the mpsL1 pseudo attP site was done on 18 tumors (lanes 5
through 22) and one metastasis (lane 23) taken from nine mice given pCSI/pLiLucB by hydrodynamic injection. Controls included no DNA (1
st round,
lane 1 and 2
nd round, lane 25), and a DNeasy performed on no tissue (lane 2) to show no contamination from the DNA isolation procedure. Normal-
appearing liver from a mouse in the pCSI/pLiLucB group (lane 3) served as the positive control. DNA isolated from a tumor in the saline-only group
served as the negative control (lane 4). PCR for the GAPDH gene showed that sufficient DNA was added to all reactions. Seven tumors and one
metastasis were subjected to the analysis in both a and c. Six tumors were analyzed by all assays (a, b and c).
doi:10.1371/journal.pone.0011367.g003
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the pCS/pLiLucB group developed tumors faster than the groups
given integrase-expressing plasmids, increased numbers of lucifer-
ase-positive cells in the liver cause higher long-term luciferase
levels. We do not believe that luciferase is an ideal readout for
overall levels of transgene expression in the liver, because the levels
detected are dependent on the distance from the surface of the
animal. In this animal model, tumors formed that may have
complicated interpretation of the luciferase levels by displacing the
normal liver away from the surface of the animal. It was the
Figure 4. Luciferase expression and the relationship between initial expression values and long-term survival. (a) TRE-MYC/LAP-tTA
transgenic mice given pCS/pLiLucB (purple diamonds), pCSmI/pLiLucB (cyan squares), or pCSI/pLiLucB (blue triangles) by hydrodynamic injection
were imaged at Day 1, Week 2, 4, 6, 8, and 10. The normalized luciferase levels were obtained by dividing the average luciferase expression in
reflective light units (RLU) at each time point by the average level at day 1 for that group. Propagation of errors was used to determine the standard
error at each time point given the division calculation (error bars). By student’s t-test of the values at day 70, the pCSI/pLiLucB group and pCS/pLiLucB
group had a p-value of 0.067, while the pCSI/pLiLucB group and pCS/pLiLucB group were significantly higher than the pCSmI/pLiLucB group
(p=0.014 and p=0.000031, respectively). (b) Each mouse is represented by one point on the scatterplot, using the day 1 luciferase value in reflective
light units (RLU) as the x-coordinate and the days of survival as the y-coordinate. The symbols and colors are identical to those used in a. The linear
line-of-best-fit was calculated by GraphPad Prism and is plotted for each group (R-squared values of pCS/pLiLucB, 0.1065; pCSmI/pLiLucB, 0.3839;
pCSI/pLiLucB, 0.0033). No R-squared values exceeded 0.95, which would have indicated that there was a trend relating transfection efficiency and
survival.
doi:10.1371/journal.pone.0011367.g004
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luciferase transgene in the liver. However, luciferase imaging did
not detect any luciferase-positive metastases (Table 1).
In order to correlate the efficiency of hydrodynamic injection
with tumor latency, the luciferase expression on day 1 was plotted
against survival time (Fig. 4b). An R-squared value exceeding
0.95 would have indicated a trend correlating transfection
efficiency and survival. The R-squared values for all groups were
lower than 0.95, regardless of the method used to calculate the
trend line, suggesting that variations in transfection efficiency may
not have affected tumor latency.
Discussion
This study represents a novel use of a genetic mouse model to
provide insights into the safety of new gene therapy methodologies in
a solid tissue. Such mouse models are available for most organs that
may be targeted by different gene therapy methods. Similar studies
using tumor-prone mouse models to investigate the incidence of
blood cancers after treatment with various viral vectors have been
used to demonstrate that newer vectorscontaining insulator elements,
weaker promoters, and/or lentiviral sequences may be safer than
those vectors originally used in clinical trials for X-SCID that became
implicated in the formation of leukemias [18,19].
Our data suggested an acceleration in tumor formation due to
hydrodynamic injection in combination with C-MYC overexpres-
sion. The mechanism whereby hydrodynamic injection stimulated
tumor formation is unknown. However, one could speculate that
the extensive cellular proliferation that occurred after hydrody-
namic injection in wild-type mice [36] may play a role. A
comparable level of cellular proliferation induced by partial
hepatectomy was reported to cause a similar acceleration in tumor
formation in this cancer model [22,23].
We hypothesized that if QC31 integrase were tumorigenic, one
would have expected a further decrease in tumor latency when
hydrodynamic injection was accompanied by QC31 integrase.
Instead, no measurable increase in C-MYC-induced tumor
formation was found, suggesting that our hypothesis that QC31
integrase would be tumorigenic in this animal model was
incorrect. No tumors taken from mice given active QC31 integrase
and the luciferase donor plasmid were found to have integrated at
a preferred pseudo attP site in the mouse genome, even though one
or two out of nineteen might have been expected to be positive by
random chance. It is unknown why the presence of either active or
inactive QC31 integrase reduced the tumorigenicity of hydrody-
namic injection. The recombination activity of QC31 integrase was
not likely to be responsible for the significantly longer tumor
latency compared to the pCS/pLiLucB and saline groups, because
the pCSmI/pLiLucB, pCSI/pLiLucB, and pCSI alone groups
were not statistically different from one another. Because the
presence of QC31 integrase protein in hepatocytes was correlated
with reduced cellular proliferation in a previous study [36],
regardless of integrase activity, one possible hypothesis is that the
decreased levels of proliferation resulted in reduced tumorigenesis
in groups receiving integrase plasmids. We could also speculate
that the immune system played a role in the effect, or that
interaction of QC31 integrase with cellular proteins [40,41] proved
to be anti-tumorigenic. It could be suggested that hydrodynamic
injection did not transfect the cells that can go on to become
cancer. However, when two oncogenes (MET and DN90-
CTNNB1) were administered to the liver of wild-type mice via
hydrodynamic injection and integrated with a transposon system,
tumors developed in most of the mice within 200 days [42]. Thus,
hydrodynamic injection has already been shown to be capable of
delivering oncogenes to tumor-forming cells within the liver.
Our mouse model revealed a statistically significant contribution
of the hydrodynamic method itself, with or without DNA, to
tumor formation. Although significant, it should be noted that the
decrease in tumor latency from hydrodynamic delivery alone
(Fig. 2b) was modest compared to the dramatic one-week median
tumor latency when shRNA or small molecule carcinogens such as
carbon tetrachloride cooperated with C-MYC in this mouse model
[23]. While hydrodynamic injection is perhaps the most robust
method of plasmid DNA delivery to mouse liver currently
available, adaptations of the method that are less disruptive would
be desirable for clinical use. For example, localized, catheter-
mediated delivery to the liver has been explored in large animal
models [3] and may have a superior safety profile compared to the
systemic delivery method used in mice.
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